ATNM Stock Summary and Trading Ideas (Actinium Pharmaceuticals (Delaware) | AMEX:ATNM)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (Delaware) trades on the AMEX stock market under the symbol ATNM.

As of March 26, 2026, ATNM stock price declined to $1.05 with 62,635 million shares trading.

ATNM has a beta of 2.07, meaning it tends to be more sensitive to market movements. ATNM has a correlation of 0.22 to the broad based SPY ETF.

ATNM has a market cap of $32.76 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATNM traded as high as $10.24 and as low as $1.02.

The top ETF exchange traded funds that ATNM belongs to (by Net Assets): VTI, VXF, IWC.

ATNM has underperformed the market in the last year with a price return of -33.5% while the SPY ETF gained +13.4%. ATNM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.0% and -11.0%, respectively, while the SPY returned -6.3% and -4.4%, respectively.

ATNM support price is $1.03 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATNM shares will trade within this expected range on the day.